AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
May 5, 2021
29864_dirs_2021-05-05_ce5fde7f-8dee-43ca-a6ef-ddc51ed9e9c5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-04-30
Reporting Person: Sanna Bastiano (EVP, Cell & Genetic Therapies)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-30 | Common Stock | F | 766 | $217.21 | Disposed | 35068 | Direct |
| 2021-05-03 | Common Stock | S | 501 | $218.06 | Disposed | 34567 | Direct |
| 2021-05-03 | Common Stock | S | 459 | $218.83 | Disposed | 34108 | Direct |
Footnotes
F1: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $218.06 (range $217.51 to $218.49).
F3: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $218.83 (range $218.52 to $219.24).